Skip to content
2000
Volume 21, Issue 17
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Rheumatoid arthritis (RA) is a common and debilitating disease. Expanded therapeutic options, targeting pro-inflammatory cytokines such as tumour necrosis factor (TNF) and interleukin-6 (IL-6), have revolutionised RA treatment. To date, efficacy data shows superiority of IL-6 inhibition over placebo, conventional disease modifying anti-rheumatic drugs such as methotrexate, and TNF inhibition. Moreover, while demonstrating some key differences in the safety profile compared with TNF inhibition (e.g. hyperlipidemia and neutropenia), these safety concerns have not, at least to date, been found to cause clinically significant adverse outcomes. Other safety parameters, such as infection and malignancy rates have been found to be comparable between IL-6 and TNF inhibition. This review explores the biology and clinical applications of IL-6 inhibition in the management of RA.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612821666150310143332
2015-05-01
2025-05-03
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612821666150310143332
Loading

  • Article Type:
    Research Article
Keyword(s): inflammation; interleukin-6; Rheumatoid arthritis; treatment
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test